Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0LUNVE
ADC Name
c208F2-F-13
Synonyms
c208F2 F-13
   Click to Show/Hide
Organization
Pierre Fabre SA.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
c208F2
  Antibody Info 
Antigen Name
Insulin-like growth factor 1 receptor (IGF1R)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
c208F2-F-13 linker
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.1
nM
CVCL_0031
Invasive breast carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.10 nM Positive IGF1R expression (IGF1R+++/++)
Method Description
MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
References
Ref 1 Antibody-drug-conjugate and its use for the treatment of cancer.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.